Direct emissions
426
tCO2e
Back to search resultsEmissions
Sustainability
Scope
REPORTED REPORTED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED ESTIMATED 
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)
Mycelium Score0.3 / 10Significant room to improveFTransparencyVery LowMinimal disclosure across key areas
Explore carbon emissions data for SK Biopharmaceuticals. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.
This profile brings together available carbon emissions data for SK Biopharmaceuticals, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. It is one entry in the Mycelium emissions database. Read how we source and check this data.
Emissions
Carbon emissions
Total yearly emissions across all scopes
41,857tCO2e(Location Based)(Mycelium adjusted)
- Reported by SK Biopharmaceuticals
- 1,362 tCO₂e
- Estimated by Mycelium
- 40,495 tCO₂e
SK Biopharmaceuticals reported 3% of the adjusted total. Mycelium estimated the remaining 97% for the categories it did not disclose.
Scope 1
tCO2e
426
Scope 2 (Location Based)
tCO2e
937
Scope 3 total
tCO2e
40,495
Figures from page 149 of the source report
Scope 3 reported
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Something wrong? Contribute to this dataset
See the scope breakdownProvenance
Emissions
Factors
0.140kgCO2e / $
Supplier specific emission factors (kgCO2e / $)
Modelled
Reported
UpstreamScope 1, 2 + upstream Scope 3
0.140
0.007
Total+ all Scope 3
–
0.007
Per US dollar of revenue. Mycelium models the upstream factor only.
Which figure should I use?
Estimating your own supply-chain emissions from spend with this company? Use Upstream Modelled. The GHG Protocol defines purchased-goods emissions as cradle-to-gate, which means this company's own operations plus its upstream supply chain. Any of those emissions the company has not disclosed are filled with modelled estimates, so a transparent company is not unfairly penalised against one that simply has not reported.
Looking at what the company filed itself? Use the Reported column. Total Reported also includes downstream emissions, such as the lifetime use of the products this company sells, which the GHG Protocol attributes to the users of those products rather than to customers buying goods and services.
Reported counts only emissions the company has filed itself. A blank or low Reported cell does not mean those emissions do not exist, just that the company has not disclosed them. When Upstream Reported sits close to Upstream Modelled, that is a positive signal: the company has disclosed most of its upstream emissions.
Sustainability
Snapshot
Based on reported data, retrieved with AI
- SK Biopharmaceuticals reported 1,362 tCO₂e in 2022.
- Scope 2 reported under the location based methodology.
According to available emissions disclosures, SK Biopharmaceuticals reported total yearly emissions of 1,362 tCO₂e in 2022. Scope 2 emissions accounted for 69% of the reported footprint, indicating purchased energy was the most significant contributor to its carbon footprint.
The company achieved a Mycelium Score of 0.3, placing it well below average for its sector for sustainability performance, and received a transparency score of 4.5, pointing to very little public detail on their key emissions.
Scope
breakdown
Scope 1 emissions
Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.
Scope 2 emissions
Indirect emissions from purchased energy, including electricity, heating and cooling.
Location based
937
tCO2eMarket based
–
tCO2eScope 3 emissions
Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.
Cat 1
Purchased goods & services
14,665
tCO2eCat 2
Capital goods
2,283
tCO2eCat 3
Fuel & energy related activities
6,738
tCO2eCat 4
Upstream transportation & distribution
885
tCO2eCat 5
Waste generated in operations
106
tCO2eCat 6
Business travel
169
tCO2eCat 7
Employee commuting
227
tCO2eCat 8
Upstream leased assets
227
tCO2eCat 9
Downstream transportation & distribution
845
tCO2eCat 10
Processing of sold products
4,549
tCO2eCat 11
Use of sold products
5,676
tCO2eCat 12
End-of-life treatment of sold products
562
tCO2eCat 13
Downstream leased assets
1,851
tCO2eCat 14
Franchises
676
tCO2eCat 15
Investments
1,036
tCO2e15 values were derived via Mycelium's normalisation process rather than reported by the company. A cell marked “ESTIMATED” is a figure the company did not disclose, modelled by Mycelium.
Verification
Independent third parties involved in checking or preparing SK Biopharmaceuticals's emissions data.
Independent assurance
Independently assured(limited assurance)by Korean Foundation for Qualityfor 2022
Contact Info
Website
–
Country
South Korea
Browse carbon emissions data by industry
Jump straight into the sectors users explore most, or view all industries.
How scoring works
How the Mycelium Score is calculated
The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs peers in the same NACE section (emissions normalised against revenue, log-scaled between the 5th and 95th percentile of each company's latest reporting year in that section; a section needs at least 5 companies to be benchmarked). The band above 6.5 is earned through verified data quality on a claimed profile: declaring every reporting category yourself (up to 2.0), preparation by a carbon accountant (2.0) and independently audited figures (2.0). The total is multiplied by the transparency score and capped at 10. A disclosure with an implausibly large figure (Scope 1 or 2 over 300 million tonnes, a Scope 3 figure over 2 billion tonnes or a total over 2.5 billion tonnes) is not scored until it has been checked.
A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. SK Biopharmaceuticals's score sits at the top of this page and in the score panel. Without a revenue figure to measure carbon intensity, or an industry classification to compare it within, a company has no score.
How the Transparency Score is calculated
The Transparency Score is the share of a company's estimated footprint that it reported itself, graded from A (very high) down to F (very low). Where a category is missing, Mycelium models what it would hold for a company of that size and industry and counts it as undisclosed, so an unreported category where the bulk of emissions sit hurts far more than a minor one. Unreported downstream categories (9 to 15) count at a quarter of their modelled size in this share; the carbon intensity behind the score still counts them in full. A Scope 3 total filed without a category breakdown earns very little credit for the part left unattributed, because it does not show which categories are inside it: a company can count business travel, leave purchased goods out entirely, and the total looks the same. Without a revenue figure the footprint cannot be modelled, so the company has no Transparency Score.
For SK Biopharmaceuticals, the single biggest gap is Purchased goods & services (Scope 3 Category 1). Mycelium estimates it accounts for around 35% of the company's estimated footprint, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.
Other material categories SK Biopharmaceuticals hasn't disclosed:
- Fuel & energy related activities (Scope 3 Category 3), around 16% of the estimated footprint
- Use of sold products (Scope 3 Category 11), around 14% of the estimated footprint
- Processing of sold products (Scope 3 Category 10), around 11% of the estimated footprint
In total, roughly 97% of SK Biopharmaceuticals's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.
Read the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)Compare SK Biopharmaceuticals with similar companies
SK Biopharmaceuticals carbon emissions FAQs
What are SK Biopharmaceuticals's carbon emissions?
In its 2022 reporting year, SK Biopharmaceuticals disclosed total emissions of 1,362 tCO2e across all scopes. Including Mycelium estimates for undisclosed categories, the adjusted total is 41,857 tCO2e. Scope 2 accounted for the largest share of the reported total, around 69%.
Does SK Biopharmaceuticals report Scope 1, Scope 2 and Scope 3 emissions?
For 2022, SK Biopharmaceuticals's available disclosure covers Scope 1 (426 tCO2e) and Scope 2 (937 tCO2e). Figures not reported by the company are shown as modelled estimates and labelled as such.
How transparent is SK Biopharmaceuticals's emissions reporting?
SK Biopharmaceuticals has a Mycelium transparency score of 4.5 out of 100. The score is the share of the company's estimated footprint that it reported itself, so an undisclosed category where most of its emissions sit weighs far more than a minor one.
Is SK Biopharmaceuticals sustainable?
Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. SK Biopharmaceuticals has a Mycelium Score of 0.3 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures and disclosure documents on this page give the fuller picture.
Is SK Biopharmaceuticals environmentally friendly?
Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. SK Biopharmaceuticals disclosed 1,362 tCO2e for 2022, and its Mycelium Score of 0.3 out of 10 shows how that performance compares with similar companies in its sector.
Learn more about our methodology and where this data comes from.